PRLD: Losses increased amid product development, but funding and patent milestones support 2027 launch

About this update from Prolight Diagnostics Ab

Operating losses widened as product development accelerated, but liquidity was bolstered by a fully subscribed SEK 100.3 million rights issue. Key patents were granted, and the Psyros system prototype was showcased, with commercialization now targeted for 2027.Original document: This is an AI-generated summary and may contain inaccuracies. Please verify any important information with the original source.

View stock analysis, news, and events for Prolight Diagnostics Ab